Wechselwirkungen · Synagis
Synagis 50 mg/0.5 ml solution for injection Synagis 100 mg/1 ml solution for injection · Abschnitt 4.5 · PDF-Seite 4
HOS-090193 · Präparat HOS-084025
Palivizumab may interfere with immune-based RSV diagnostic tests, such as some antigen detection based assays. In addition, palivizumab inhibits virus replication in cell culture and, therefore, may also interfere with viral culture assays. Palivizumab does not interfere with reverse transcriptase polymerase chain reaction-based assays. Assay interference could lead to false-negative RSV diagnostic test results. Therefore, diagnostic test results, when obtained, should be used in conjunction with clinical findings to guide medical decisions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-10-11T08:14:00Z · SHA-256 80b341ab31afe95db5c42fa61205421fb02b06bd1c5fb252bf6a42f441c92dde · Passage fcfdc29a715c8f008363a2428d3aa081e67385d07dd09a2becf1fc9e1c751c1d · Zeichen 649–1196 im Abschnitt